HOME Research Insight Major Players in the Market Include Caris Life Sciences. (U.S.), Helomics Corporation (U.S.),in the Global Tumor Profiling Market



Major Players in the Market Include Caris Life Sciences. (U.S.), Helomics Corporation (U.S.),in the Global Tumor Profiling Market


Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Neogenomics Laboratories (U.S.), HTG Molecular Diagnostic (U.S.), and Genomic Health (U.S.), are the leading players in the global cancer/tumor profiling market. The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include Caris Life Sciences. (U.S.), Helomics Corporation (U.S.), and NanoString Technologies, Inc. (U.S.).

Illumina, Inc. seeks to build integrated solutions to enhance the understanding of genetics and health to improve biological research projects. The company strategically concentrates on developing core technologies, assay chemistries, systems, and software to expedite the collection, analysis, and application of biological information. For this purpose, the company primarily pursues the strategies of collaborations and agreements. For instance, in December 2015; Illumina, Inc. entered into an agreement with Novogene (China), to jointly develop genomic applications in the field of reproductive health and oncology testing.

QIAGEN aims to develop and deliver new test solutions to enhance scientific innovations and optimize productivity. The company pursues the strategy of collaborations to strengthen its presence and increase its share in the cancer/tumor profiling market. In accordance with this, in June 2015, QIAGEN entered into a strategic collaboration with Hitachi High-Technologies (Japan) to provide innovative solutions for molecular testing. The company has incurred loss in their revenue from USD 1.17 Billion in 2014 to USD 1.11 Billion in 2015 due to adverse currency movement.QIAGEN N.V. (Netherlands) held the third-largest position in the cancer/tumor profiling market in 2015. The company adopted new product launches as its key strategy to strengthen its position in the market. In the past three years, the company launched various solutions, such as digital NGS solutions, GeneRead DNAseq V2 gene panels, QIAxpert system, and CLC cancer/tumor profiling suite.

NeoGenomics Laboratories, Inc. is a provider of cancer genetics testing and information services. The company mainly focuses on launching new products to expand its product portfolio. For instance, in December 2015, NoeGenomics Laboratories launched two new tests, the NeoLAB Solid Tumor Monitor and the NeoLAB BTK Inhibitor-acquired Resistance Test, for monitoring solid tumors and predicting the response of BTK inhibitors. Similarly, in September 2015, the company introduced a NeoSITE Cervical FISH assay. The company also focuses on acquisitions to increase its market share in the cancer profiling market. In accordance with this, in December 2015, NoeGenomics Laboratories acquired Clarient, Inc. (U.S.) and its subsidiary Clarient Diagnostic Services, Inc. (U.S.), provider of cancer diagnostic tests.

As a major growth strategy, HTG Molecular Diagnostics mainly focuses on launching new products to expand its product portfolio. In October 2015, the company launched the HTG EdgeSeq DLBCL Cell of Origin Assay and the HTG EdgeSeq Lymphoma Panel for the diffusion of Large B-Cell Lymphomas for research use only. Similarly, in February, it launched the HTG EdgeSeq Immuno-Oncology Assay to measure the mRNA expression of 549 genes in the host immune response to tumors. In 2015, HTG Molecular Diagnostics’ revenue increased to USD 3.7 million as compared to USD 2.3 million in 2014.

Genomic Health Inc. is a global provider of genomic-based diagnostic tests for the early detection of cancer and its treatment. As a key business growth strategy, Genomic Health mainly focuses on launching new products to expand its product portfolio. In line with this, in June 2016, Genomic Health launched Oncotype SEQ Liquid Select, noninvasive liquid biopsy tests which help to determine genomic alteration occurs in cancer patients. The company also focuses on collaborations to strengthen its presence and increase its share in the cancer/tumor profiling market. For instance, in June 2016, Genomic Health, Inc. entered into a strategic collaboration with Epic Sciences (U.S.) to market the AR-V7 liquid biopsy test in the U. S.

Companies in the cancer/tumor profiling market are majorly focusing on new product launches for strengthening their market share; this strategy accounted for 48% of the total number of strategic developments undertaken by key players in this market.

Related Reports:

Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray)- Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports